We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$7.99B
AUM Growth
+$1.36B
Cap. Flow
+$167M
Cap. Flow %
2.09%
Top 10 Hldgs %
82.62%
Holding
149
New
30
Increased
33
Reduced
21
Closed
40

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$40.6M
2
TSRO
TESARO, Inc.
TSRO
+$32.2M
3
BPMC
Blueprint Medicines
BPMC
+$30.2M
4
NKTR icon
Nektar Therapeutics
NKTR
+$25.8M
5
FOLD
Amicus Therapeutics
FOLD
+$22.8M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$21.1M
2
INCY icon
Incyte
INCY
+$18M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.37M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$5.83M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.72M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.57%
2 Consumer Discretionary 23.48%
3 Healthcare 17.53%
4 Communication Services 0.15%
5 Materials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
76
DELISTED
Audentes Therapeutics, Inc
BOLD
$4.51M 0.06%
150,000
-50,000
-25% -$1.69M
NG icon
77
NovaGold Resources
NG
$2.54B
$4.33M 0.05%
+1,000,000
New +$4.01M
ACET icon
78
Adicet Bio
ACET
$77.6M
$4.31M 0.05%
+4,018
New +$7.37M
AGIO icon
79
CALL
Agios Pharmaceuticals
AGIO
$2.08B
$4.09M 0.05%
50,000
-50,000
-50% -$3.86M
DRNA
80
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.06M 0.05%
+425,000
New +$4.58M
SYBX
81
DELISTED
Synlogic
SYBX
$3.75M 0.05%
26,667
-10,000
-27% -$1.55M
IFRX icon
82
InflaRx
IFRX
$243M
$3.6M 0.05%
+125,000
New +$3.3M
TGTX icon
83
TG Therapeutics
TGTX
$8.19B
$3.55M 0.04%
250,000
-150,000
-38% -$1.92M
VRDN icon
84
Viridian Therapeutics
VRDN
$2.2B
$3.5M 0.04%
33,333
+26,666
+400% +$2.9M
IRWD icon
85
Ironwood Pharmaceuticals
IRWD
$586M
$3.35M 0.04%
258,954
-358,200
-58% -$4.46M
PTLA
86
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.27M 0.04%
100,000
-50,000
-33% -$2.19M
CMTA
87
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.03M 0.04%
+200,000
New +$3.25M
SGMO
88
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.85M 0.04%
+150,000
New +$3.21M
ACHN
89
DELISTED
Achillion Pharmaceuticals
ACHN
$2.78M 0.03%
750,000
– –
CMRX
90
DELISTED
Chimerix, Inc.
CMRX
$2.6M 0.03%
500,000
– –
ADVM
91
DELISTED
Adverum Biotechnologies
ADVM
$2.32M 0.03%
+40,000
New +$2.49M
SNDX icon
92
Syndax Pharmaceuticals
SNDX
$1.7B
$2.13M 0.03%
150,000
– –
MRNS
93
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.91M 0.02%
125,000
+75,000
+150% +$1.79M
NTLA icon
94
Intellia Therapeutics
NTLA
$1.51B
$1.9M 0.02%
90,000
-160,000
-64% -$3.93M
KURA icon
95
Kura Oncology
KURA
$793M
$1.88M 0.02%
100,000
– –
NERV icon
96
Minerva Neurosciences
NERV
$191M
$1.88M 0.02%
37,500
+6,087
+19% +$292K
QTTB icon
97
Q32 Bio
QTTB
$435M
$1.87M 0.02%
+5,556
New +$1.87M
KRYS icon
98
Krystal Biotech
KRYS
$10.7B
$1.51M 0.02%
150,000
– –
ATYR
99
aTyr Pharma
ATYR
$47.4M
$1.32M 0.02%
35,714
– –
RNAC icon
100
Cartesian Therapeutics
RNAC
$218M
$1.27M 0.02%
+4,167
New +$1.19M
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2018 Portfolio in Review

As of Q1 2018, Artal Group held 149 positions worth $7.99B, up 21% from $6.63B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group's Q1 2018 filing shows 30 new, 33 increased, 21 reduced and 40 closed positions. Its largest new stake was Kyntra Bio: 10,000 shares worth $11.6M. The largest sale was Neurocrine Biosciences, an estimated $21.1M.

By sector, the portfolio is most concentrated in Consumer Staples at 44% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2018 buy was Kyntra Bio: 10,000 shares worth $11.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q1 2018, an estimated $40.6M increase.
  • Artal Group's biggest Q1 2018 reduction was Incyte, cutting an estimated $18M.
  • Artal Group fully exited Neurocrine Biosciences in Q1 2018, selling an estimated $21.1M.
  • Artal Group's ten largest holdings make up 83% of its $7.99B portfolio in Q1 2018.
  • Artal Group opened 30 new positions and closed 40 in Q1 2018.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $7.99B.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.